# Jae H. Park

Source: https://onco.cc/people/jae-park/  
OnCo record `jae-park` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ran the long-term CD19 CAR-T studies in adult leukaemia that showed durable remissions and defined toxicity risk.

## Summary

Jae H. Park is Director of the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center. He is known for running the long-term CD19 CAR-T studies in adult acute lymphoblastic leukaemia that showed durable remissions and defined toxicity risk, leading MSK's 19-28z CAR-T trials. That work showed that low disease burden at infusion predicts durable remission and lower toxicity. His selected paper reports long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukaemia, and he now directs cellular immunotherapy at MSK.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Cellular Therapy Service
- Specialisms: CAR-T therapy; Acute lymphoblastic leukaemia; Cellular immunotherapy

## Sources

- MSK profile: https://www.mskcc.org/cancer-care/doctors/jae-park
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Park%20JH%5BAuthor%5D

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)

---
JSON: https://onco.cc/api/v1/entities/jae-park.json